{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:08:35Z","timestamp":1791212915567,"version":"4.1.0"},"reference-count":42,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The majority of disease-specific complications in chronic lymphocytic leukemia (CLL), notably infection and autoimmunity, relate to the underlying alterations in immune function. Both cellular and humoral immunity are impaired with qualitative and quantitative defects in B cells, T cells, NK cells, neutrophils and the monocyte\/macrophage lineage. Virtually all patients have reduced immunoglobulin levels, even in early stages, and this is associated with an increased frequency and severity of infection. Although prophylactic intravenous immunoglobulin may be of clinical benefit in selected patients, it does not reduce mortality and is certainly not cost-effective. Autoimmune complications occur in up to a quarter of CLL patients and predominantly target blood cells. Autoimmune hemolytic anemia (AHA) is the most common manifestation; immune thrombocytopenia, pure red cell aplasia and autoimmune neutropenia are less common, while non-hematological autoimmunity is rare. The UK CLL4 trial is the largest prospective trial in CLL to examine the significance of both a positive direct antiglobulin test (DAT) and AHA. The study confirmed the usefulness of the DAT in predicting the development of AHA or not, demonstrated that AHA occurred more frequently in patients receiving treatment with chlorambucil or fludarabine alone compared with the combination of fludarabine and cyclophosphamide, and showed that a positive DAT and the development of AHA were poor prognostic markers. Management of CLL-associated autoimmunity rests on good supportive care and the use of immunosuppressive therapies such as steroids and cyclosporine. Splenectomy remains useful, and monoclonal antibodies (rituximab and alemtuzumab) have given promising results.<\/jats:p>","DOI":"10.1182\/asheducation-2008.1.450","type":"journal-article","created":{"date-parts":[[2008,12,11]],"date-time":"2008-12-11T15:12:58Z","timestamp":1229008378000},"page":"450-456","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":120,"title":["Disease-Specific Complications of Chronic Lymphocytic Leukemia"],"prefix":"10.1182","volume":"2008","author":[{"given":"Claire","family":"Dearden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111711115038100_R1","doi-asserted-by":"crossref","unstructured":"Ghia P, Scielzo C, Frenquelli M, et al. From normal to clonal B cells: chronic lymphocytic leukemia (CLL) at the crossroad between neoplasia and autoimmunity. Autoimmun Rev. 2007;7:127\u2013131.","DOI":"10.1016\/j.autrev.2007.02.014"},{"key":"2019111711115038100_R2","doi-asserted-by":"crossref","unstructured":"Murray F, Darzentas N, Hadzidimitriou A, et al. Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis. Blood. 2008;111:1524\u20131533.","DOI":"10.1182\/blood-2007-07-099564"},{"key":"2019111711115038100_R3","doi-asserted-by":"crossref","unstructured":"Scrivener S, Goddard RV, Kaminski ER, et al. Abnormal T-cell function in B-cell chronic lymphocytic leukaemia. Leuk Lymphoma. 2003;44:383\u2013389.","DOI":"10.1080\/1042819021000029993"},{"key":"2019111711115038100_R4","doi-asserted-by":"crossref","unstructured":"Mackus WJ, Frakking FN, Grummels A, et al. Expansion of CMV-specific CD8+CD45RA+. Blood. 2003;102:1057\u20131063.","DOI":"10.1182\/blood-2003-01-0182"},{"key":"2019111711115038100_R5","doi-asserted-by":"crossref","unstructured":"Gorgun G, Holderried TA, Zahrieh D, et al. Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. J Clin Invest. 2005;115:1797\u20131805.","DOI":"10.1172\/JCI24176"},{"key":"2019111711115038100_R6","doi-asserted-by":"crossref","unstructured":"Buggins AG, Patten PE, Richards J, et al. Tumor-derived IL-6 may contribute to the immunological defect in CLL. Leukemia. 2008; 22:1084\u20131087.","DOI":"10.1038\/sj.leu.2405015"},{"key":"2019111711115038100_R7","doi-asserted-by":"crossref","unstructured":"Cantwell M, Hua T, Pappas J, et al. Acquired CD40-ligand deficiency in chronic lymphocytic leukemia. Nat Med. 1997;3:984\u2013989.","DOI":"10.1038\/nm0997-984"},{"key":"2019111711115038100_R8","doi-asserted-by":"crossref","unstructured":"Kay NE, Zarling JM. Impaired natural killer activity in patients with chronic lymphocytic leukemia is associated with a deficiency of azurophilic cytoplasmic granules in putative NK cells. Blood. 1984;63:305\u2013309.","DOI":"10.1182\/blood.V63.2.305.bloodjournal632305"},{"key":"2019111711115038100_R9","doi-asserted-by":"crossref","unstructured":"Nuckel H, Rebmann V, Durig J, et al. HLA-G expression is associated with an unfavorable outcome and immunodeficiency in chronic lymphocytic leukemia. Blood. 2005;105:1694\u20131698.","DOI":"10.1182\/blood-2004-08-3335"},{"key":"2019111711115038100_R10","doi-asserted-by":"crossref","unstructured":"Itala M, Vainio O, Remes K. Functional abnormalities in granulocytes predict susceptibility to bacterial infections in chronic lymphocytic leukaemia. Eur J Haematol. 1996;57:46\u201353.","DOI":"10.1111\/j.1600-0609.1996.tb00489.x"},{"key":"2019111711115038100_R11","unstructured":"Schlesinger M, Broman I, Lugassy G. The complement system is defective in chronic lymphatic leukemia patients and in their healthy relatives. Leukemia. 1996;10:1509\u20131513"},{"key":"2019111711115038100_R12","doi-asserted-by":"crossref","unstructured":"Davey FR, Kurec AS, Tomar RH, et al. Serum immunoglobulins and lymphocyte subsets in chronic lymphocytic leukemia. Am J Clin Pathol. 1987;87:60\u201365.","DOI":"10.1093\/ajcp\/87.1.60"},{"key":"2019111711115038100_R13","doi-asserted-by":"crossref","unstructured":"Sinisalo M, Aittoniemi J, Koski T, et al. Similar humoral immunity parameters in chronic lymphocytic leukemia patients independent of VH gene mutation status. Leuk Lymphoma. 2004;45:2451\u20132454.","DOI":"10.1080\/10428190400007763"},{"key":"2019111711115038100_R14","doi-asserted-by":"crossref","unstructured":"Alexandrescu DT, Wiernik PH. Serum globulins as marker of immune restoration after treatment with high-dose rituximab for chronic lymphocytic leukemia. Med Oncol.2008 Jan 5. Epub ahead of print.","DOI":"10.1007\/s12032-007-9037-8"},{"key":"2019111711115038100_R15","doi-asserted-by":"crossref","unstructured":"Arens R, Nolte MA, Tesselaar K, et al. Signaling through CD70 regulates B cell activation and IgG production. J Immunol. 2004;173:3901\u20133908.","DOI":"10.4049\/jimmunol.173.6.3901"},{"key":"2019111711115038100_R16","doi-asserted-by":"crossref","unstructured":"Sampalo A, Brieva JA. Humoral immunodeficiency in chronic lymphocytic leukemia: role of CD95\/CD95L in tumoral damage and escape. Leuk Lymphoma. 2002;43:881\u2013884.","DOI":"10.1080\/10428190290017033"},{"key":"2019111711115038100_R17","doi-asserted-by":"crossref","unstructured":"Boughton BJ, Jackson N, Lim S, et al. Randomized trial of intravenous immunoglobulin prophylaxis for patients with chronic lymphocytic leukaemia and secondary hypogammaglobulinaemia. Clin Lab Haematol. 1995;17:75\u201380.","DOI":"10.1111\/j.1365-2257.1995.tb00322.x"},{"key":"2019111711115038100_R18","unstructured":"Molica S, Musto P, Chiurazzi F, et al. Prophylaxis against infections with low-dose intravenous immunoglobulins (IVIG) in chronic lymphocytic leukemia. Results of a crossover study. Haematologica. 1996;81:121\u2013126."},{"key":"2019111711115038100_R19","doi-asserted-by":"crossref","unstructured":"Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia. Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. N Engl J Med. 1988;319:902\u2013907.","DOI":"10.1056\/NEJM198810063191403"},{"key":"2019111711115038100_R20","doi-asserted-by":"crossref","unstructured":"Morrison VA. Management of infectious complications in patients with chronic lymphocytic leukemia. Hematology (Am Soc Hematol Educ Program).2007;332\u2013338.","DOI":"10.1182\/asheducation-2007.1.332"},{"key":"2019111711115038100_R21","doi-asserted-by":"crossref","unstructured":"Sinisalo M, Vilpo J, Itala M, et al. Antibody response to 7-valent conjugated pneumococcal vaccine in patients with chronic lymphocytic leukaemia. Vaccine. 2007;26:82\u201387.","DOI":"10.1016\/j.vaccine.2007.10.053"},{"key":"2019111711115038100_R22","doi-asserted-by":"crossref","unstructured":"Van der Velden AM, Velzen-Blad H, Claessen AM, et al. The effect of ranitidine on antibody responses to polysaccharide vaccines in patients with B-cell chronic lymphocytic leukaemia. Eur J Haematol. 2007;79:47\u201352.","DOI":"10.1111\/j.1600-0609.2007.00862.x"},{"key":"2019111711115038100_R23","doi-asserted-by":"crossref","unstructured":"Hamblin TJ. Autoimmune complications of chronic lymphocytic leukemia. Semin Oncol. 2006;33:230\u2013239.","DOI":"10.1053\/j.seminoncol.2006.01.011"},{"key":"2019111711115038100_R24","doi-asserted-by":"crossref","unstructured":"Mittal S, Blaylock MG, Culligan DJ, et al. A high rate of CLL phenotype lymphocytes in autoimmune hemolytic anemia and immune thrombocytopenic purpura. Haematologica. 2008;93:151\u2013152.","DOI":"10.3324\/haematol.11822"},{"key":"2019111711115038100_R25","doi-asserted-by":"crossref","unstructured":"Hall AM, Vickers MA, McLeod E, et al. Rh autoantigen presentation to helper T cells in chronic lymphocytic leukemia by malignant B cells. Blood. 2005;105:2007\u20132015.","DOI":"10.1182\/blood-2003-10-3563"},{"key":"2019111711115038100_R26","unstructured":"Lewis FB, Schwartz RS, Dameshek W. X-radiation and alkylating agents as possible \u201ctrigger\u201d mechanisms in the autoimmune complications of malignant lymphoproliferative disease. Clin Exp Immunol. 1966;1:3\u201311."},{"key":"2019111711115038100_R27","doi-asserted-by":"crossref","unstructured":"Catovsky D, Richards S, Matutes E, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet. 2007;370:230\u2013239.","DOI":"10.1016\/S0140-6736(07)61125-8"},{"key":"2019111711115038100_R28","doi-asserted-by":"crossref","unstructured":"Dearden C, Wade R, Else M, et al. The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia. Blood. 2008;111:1820\u20131826.","DOI":"10.1182\/blood-2007-07-101303"},{"key":"2019111711115038100_R29","doi-asserted-by":"crossref","unstructured":"Borthakur G, O\u2019Brien S, Wierda WG, et al. Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab\u2014incidence and predictors. Br J Haematol. 2007;136:800\u2013805.","DOI":"10.1111\/j.1365-2141.2007.06513.x"},{"key":"2019111711115038100_R30","doi-asserted-by":"crossref","unstructured":"Mauro FR, Foa R, Cerretti R, et al. Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features. Blood. 2000;95:2786\u20132792.","DOI":"10.1182\/blood.V95.9.2786.009k30_2786_2792"},{"key":"2019111711115038100_R31","unstructured":"Barcellini W, Capalbo S, Agostinelli RM, et al. Relationship between autoimmune phenomena and disease stage and therapy in B-cell chronic lymphocytic leukemia. Haematologica. 2006;91:1689\u20131692."},{"key":"2019111711115038100_R32","doi-asserted-by":"crossref","unstructured":"Kyasa MJ, Parrish RS, Schichman SA, et al. Autoimmune cytopenia does not predict poor prognosis in chronic lymphocytic leukemia\/small lymphocytic lymphoma. Am J Hematol. 2003;74:1\u20138.","DOI":"10.1002\/ajh.10369"},{"key":"2019111711115038100_R33","doi-asserted-by":"crossref","unstructured":"Zent CS, Ding W, Schwager SM, et al. The prognostic significance of cytopenia in chronic lymphocytic leukaemia\/small lymphocytic lymphoma. Br J Haematol. 2008;141:615\u2013621.","DOI":"10.1111\/j.1365-2141.2008.07086.x"},{"key":"2019111711115038100_R34","doi-asserted-by":"crossref","unstructured":"Cortes J, O\u2019Brien S, Loscertales J, et al. Cyclosporin A for the treatment of cytopenia associated with chronic lymphocytic leukemia. Cancer. 2001;92:2016\u20132022.","DOI":"10.1002\/1097-0142(20011015)92:8<2016::AID-CNCR1539>3.0.CO;2-E"},{"key":"2019111711115038100_R35","doi-asserted-by":"crossref","unstructured":"Hill J, Walsh RM, McHam S, et al. Laparoscopic splenectomy for autoimmune hemolytic anemia in patients with chronic lymphocytic leukemia: a case series and review of the literature. Am J Hematol. 2004;75:134\u2013138.","DOI":"10.1002\/ajh.10472"},{"key":"2019111711115038100_R36","doi-asserted-by":"crossref","unstructured":"D\u2019Arena G, Laurenti L, Capalbo S, et al. Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia. Am J Hematol. 2006;81:598\u2013602.","DOI":"10.1002\/ajh.20665"},{"key":"2019111711115038100_R37","doi-asserted-by":"crossref","unstructured":"Gupta N, Kavuru S, Patel D, et al. Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia. Leukemia. 2002;16:2092\u20132095.","DOI":"10.1038\/sj.leu.2402676"},{"key":"2019111711115038100_R38","doi-asserted-by":"crossref","unstructured":"Karlsson C, Hansson L, Celsing F, et al. Treatment of severe refractory autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab (humanized CD52 monoclonal antibody). Leukemia. 2007;21:511\u2013514.","DOI":"10.1038\/sj.leu.2404512"},{"key":"2019111711115038100_R39","doi-asserted-by":"crossref","unstructured":"Visco C, Ruggeri M, Laura EM, et al. Impact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemia. Blood. 2008;111:1110\u20131116.","DOI":"10.1182\/blood-2007-09-111492"},{"key":"2019111711115038100_R40","doi-asserted-by":"crossref","unstructured":"Provan D, Butler T, Evangelistica ML, et al. Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults. Haematologica. 2007;92:1695\u20131698.","DOI":"10.3324\/haematol.11709"},{"key":"2019111711115038100_R41","doi-asserted-by":"crossref","unstructured":"Ghazal H. Successful treatment of pure red cell aplasia with rituximab in patients with chronic lymphocytic leukemia. Blood. 2002;99:1092\u20131094.","DOI":"10.1182\/blood.V99.3.1092"},{"key":"2019111711115038100_R42","doi-asserted-by":"crossref","unstructured":"Dungarwalla M, Marsh JC, Tooze JA, et al. Lack of clinical efficacy of rituximab in the treatment of autoimmune neutropenia and pure red cell aplasia: implications for their pathophysiology. Ann Hematol. 2007;86:191\u2013197.","DOI":"10.1007\/s00277-006-0202-5"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2008\/1\/450\/786606\/450_456ash.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2008\/1\/450\/786606\/450_456ash.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T16:12:07Z","timestamp":1574007127000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2008\/1\/450\/95858\/DiseaseSpecific-Complications-of-Chronic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1,1]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2008.1.450","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,1,1]]}}}